Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN.
E-MYCIN E vs ERYTHROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."